高危与极高危前列腺癌分层对适形放疗联合雄激素剥夺治疗结局的相关性
本研究评估203例高危或极高危前列腺癌患者接受适形放疗(前列腺78-82 Gy,盆腔淋巴结46-50 Gy)联合雄激素剥夺治疗(6个月-2年)的结局,中位随访50个月。按2014及2015版NCCN指南分为高危与极高危亚组,分层对4年生化无病生存无预测价值,仅PSA≥40 ng/ml在多因素分析中预测不良结局;远处失败为主而局部复发罕见。
要点
- 高危与极高危分层对4年生化无病生存无预测价值。
- 仅PSA≥40 ng/ml在多因素分析中预测不良结局(HR 3.75和3.25)。
- 远处失败为主、局部复发罕见,提示需改进全身治疗而非强化局部治疗。
核心结论
- 高危与极高危前列腺癌患者接受适形放疗联合雄激素剥夺治疗结局良好,但NCCN高危/极高危分层无预测价值,仅PSA≥40 ng/ml预测不良结局。
研究设计与样本
- 2001年11月至2012年3月纳入203例高危前列腺癌患者,接受前列腺78-82 Gy、盆腔淋巴结46-50 Gy适形放疗联合雄激素剥夺治疗6个月-2年,中位随访50个月(12-142个月)。
- 按2014版及修订2015版NCCN指南形成四种极高危/高危分组,采用Kaplan-Meier估计、log rank检验及单因素和多因素Cox回归分析。
主要发现
- 203例中30例(15%)出现失败,中位失败时间30个月(4-76个月)。
- 全队列4年生化无病生存率为87%(95%CI:82-92%)。
- 各NCCN亚组的4年生化无病生存、前列腺癌特异性生存和总生存相当。
- 多因素分析中仅PSA≥40 ng/ml预测4年生化无病生存或无转移生存(HR:3.75和3.25,p<0.005)。
关键数值与推荐
- 生化失败采用Phoenix定义。
- 多因素分析仅PSA≥40 ng/ml对4年生化无病生存或无转移生存有预测价值(HR:3.75和3.25,p<0.005)。
临床怎么用
- 高危前列腺癌患者接受适形剂量递增放疗联合雄激素剥夺治疗可获得良好结局。
- 按2014或修订2015版NCCN标准分为高危与极高危亚组不影响治疗结局判断。
- 仅PSA≥40 ng/ml提示预后不良,远处失败为主而局部复发罕见,提示应改进全身治疗而非强化局部治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate outcomes in prostate cancer patients classified as high-risk (HR) or very high-risk (VHR) who were treated with conformal radiation therapy (CRT) and androgen deprivation therapy (ADT). METHODS: Between 11/2001 and 3/2012, 203 patients with HR disease received CRT to the prostate (78-82 Gy) and pelvic lymph nodes (46-50 Gy) with ADT (6 m-2 years). Median follow-up was 50 months (12 m-142 m). Biochemical failure was defined according to Phoenix definition. Imaging studies were used to identify local, regional or metastatic failure. Four different VHR/HR groupings were formed using the 2014 and revised 2015 NCCN guidelines. Differences were examined using Kaplan Meier (KM) estimates with log rank test and uni- and multivariate Cox regression analysis (MVA). RESULTS: Failure occurred in 30/203 patients (15%). Median time to failure was 30 m (4 m-76 m). KM estimate of 4 year biochemical disease free survival (b-DFS) for the entire cohort was 87% (95%CI: 82-92%). Four year KM survival estimates for b-DFS, PCSS and OS were comparable for each NCCN subgroup. On univariate analysis, the NCCN subgroups were not predictive of b-DFS at 4 years, however, DMFS was worse for both VHR subgroups (p = .03and .01) respectively. Cox univariate analysis was also significant for: PSA ≥40 ng/ml p = 0.001; clinical stages T2c p = .004, T3b p = .02 and > 4 cores with Gleason score 8-10 p < .03. On MVA, only PSA ≥ 40 ng/ml was predictive for b-DFS or MFS at 4 years (HR: 3.75 and 3.25, p < 0.005). CONCLUSION: Patients with HR and VHR disease treated with CRT and ADT had good outcomes. Stratification into HR and VHR sub-groups provided no predictive value. Only PSA ≥40 ng/ml predicted poor outcomes on MVA. Distant failure was dominant and local recurrence rare, suggesting that improved systemic treatment rather than intensification of local therapy is needed. Patients with high-risk prostate cancer are most often treated with conformal dose escalated radiation therapy with androgen deprivation. Stratification into high versus very high-risk subgroups using 2014 or revised 2015 National Comprehensive Cancer Network (NCCN) criteria did not impact treatment outcomes. Only Prostate Serum Antigen (PSA) ≥40 ng/ml was predictive of poor prognosis. Distant failure was dominant and local recurrence uncommon which challenges the notion that intensification of local therapy will further improve outcomes in patients with high-risk disease.
引用
- Saad A, Goldstein J, Lawrence YR, et al. Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation? Radiat Oncol. 2017. PMID: 28061904. doi:10.1186/s13014-016-0743-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。